Abstract
New data from Wang and colleagues show that complement C3 suppresses the function of CD8+ tumor-infiltrating T cells by inhibiting IL10 production, and targeting the complement receptors C3aR and C5aR enhances the antitumor activity of immune checkpoint blockade. Their results not only define a new role of complement receptors as T-cell coinhibitory receptors, but also are useful in the development of novel strategies to improve the effectiveness of cancer immunotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 953-955 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 6 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2016 |
ASJC Scopus subject areas
- Oncology